Desperate hope: gene therapy tested in one patient with rare blindness

NCT ID NCT03672968

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This expanded access program gave a single patient with Leber Hereditary Optic Neuropathy (a genetic cause of vision loss) an experimental gene therapy called GS010. The treatment was injected into both eyes to test safety. Only one person was involved, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GS010 (gene therapy)

What this could lead to

If successful, this could provide a treatment option for patients with this rare genetic eye disease.

What could go wrong

This is a single-patient expanded access program, not a formal trial. Results may not apply to others, and risks include injection-related complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY (OPTIC, ATROPHY, HEREDITARY, LEBER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Atrophy Eye Diseases, Hereditary eye disorder hereditary disease inborn mitochondrial metabolism disorder Leber hereditary optic neuropathy neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.